The delivery of nano-formulated drugs to solid tumours is selectively increased by co-application of the vascular disrupting agent CA4P
Kitowski, A.; Heise, C.; Sperling, S.; Hotz, J.; Bajic, D.; Rubey, M.; Klar, K.; Hoefner, G.; Vollaire, J.; Josserand, V.; Coll, J.-L.; Thorn-Seshold, O.; Marinkovic, P.; Thorn-Seshold, J.
Show abstract
Improving the efficacy of existing cytotoxic chemotherapeutics requires increasing drug delivery to tumours while minimising systemic toxicity. Formulating these drugs as nanoparticles can reduce their exposure to healthy tissues, but broadly applicable strategies to enhance tumoral accumulation are lacking. Here, we show that co-administering small molecule vascular disrupting agents together with nanoparticle formulations (e.g. diagnostic reporters, or clinical drugs irinotecan and doxorubicin) increases their tumoral uptake by up to threefold, without raising systemic exposure. In a syngeneic mouse model of triple-negative breast cancer, this enhancement diminished when co-treatments were repeated, limiting its therapeutic benefit. However, since most solid tumour types are susceptible to vascular disrupting agents, this approach may be a broadly applicable strategy to improve the selectivity of drug delivery: with particular relevance for single dose use in diagnostic or research settings. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=101 SRC="FIGDIR/small/669501v1_ufig1.gif" ALT="Figure 1"> View larger version (36K): org.highwire.dtl.DTLVardef@a5b07corg.highwire.dtl.DTLVardef@1e5dcd2org.highwire.dtl.DTLVardef@49134org.highwire.dtl.DTLVardef@1d90aae_HPS_FORMAT_FIGEXP M_FIG C_FIG
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Dual-targeted nanoparticulate drug delivery systems for enhancing triple-negative breast cancer treatment 93%
- Comparative evaluation of bolus and fractionated administration modalities for two antibody-cytokine fusions in immunocompetent tumor-bearing mice 93%
- {Pi}-{Pi} Interactions Stabilize PeptoMicelle-Based Formulations of Pretomanid Derivatives Leading to Promising Therapy Against Tuberculosis in Zebrafish and Mouse Models 93%
Similar papers in this journal
- Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance 95%
- Lipophilic Nanocrystal Prodrug-Release Defines the Extended Pharmacokinetic Profiles of a Year-Long Cabotegravir 95%
- Systemic Brain Tumor Delivery of Synthetic Protein Nanoparticles for Glioblastoma Therapy 93%
Similar papers in this journal
- Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: the phase I/II first-in-human MATINS trial 92%
- Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in-vivo CAR-T therapy for inflamm-aging 92%
- Synthetically mannosylated antigens induce antigen-specific humoral tolerance and reduce anti-drug antibody responses to immunogenic biologics 90%
Similar papers in this journal
- TUB-010, a novel anti-CD30 antibody-drug conjugate based on Tub-tag technology, widens the therapeutic window by reducing toxicity while maintaining high efficacy 95%
- Development of antibody-drug conjugates targeting L1CAM to treat metastatic cancer 93%
- Immunotherapy with immunocytokines and PD-1 blockade enhances the anticancer activity of small molecule-drug conjugates targeting carbonic anhydrase IX 93%
Similar papers in this journal
- In vivo optical metabolic imaging of long-chain fatty acid uptake in orthotopic models of triple negative breast cancer 93%
- The defined TLR3 agonist, Nexavant, exhibits anti-cancer efficacy and potentiates anti-PD-1 antibody therapy by enhancing immune cell infiltration. 92%
- GABA(A) receptor activation drives GABARAP-Nix mediated autophagy to radiation-sensitize primary and brain-metastatic lung adenocarcinoma tumors 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.